Vigil Neuroscience, Inc. VIGL
We take great care to ensure that the data presented and summarized in this overview for Vigil Neuroscience, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VIGL
View all-
Atlas Venture Life Science Advisors, LLC5.84MShares$47 Million10.21% of portfolio
-
Beryl Capital Management LLC Redondo Beach, CA4.61MShares$37.1 Million5.55% of portfolio
-
Northpond Ventures, LLC4.21MShares$33.9 Million51.65% of portfolio
-
Glazer Capital, LLC New York, NY3.01MShares$24.2 Million0.86% of portfolio
-
Oddo Bhf Asset Management Sas Paris, I02.3MShares$18.5 Million0.72% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT1.58MShares$12.7 Million0.01% of portfolio
-
683 Capital Management, LLC New York, NY1.26MShares$10.2 Million0.79% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$10.2 Million0.0% of portfolio
-
Gabelli Funds LLC Rye, NY1.19MShares$9.58 Million0.07% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ1.09MShares$8.81 Million0.47% of portfolio
Latest Institutional Activity in VIGL
Top Purchases
Top Sells
About VIGL
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VIGL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 05
2025
|
Atlas Venture Fund Xii, L.P. |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,027,978
-100.0%
|
-
|
|
Aug 05
2025
|
Atlas Venture Fund Xii, L.P. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,808,896
-100.0%
|
-
|
|
Aug 05
2025
|
Mary Thistle |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Aug 05
2025
|
Haeberlein Samantha L. Budd |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,000
-100.0%
|
-
|
|
Aug 05
2025
|
Jennifer Lynn Ziolkowski Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,000
-100.0%
|
-
|
|
Aug 05
2025
|
Stefan Vitorovic |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Aug 05
2025
|
Bruce Booth |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,836,874
-100.0%
|
-
|
|
Aug 05
2025
|
Bruce Booth |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Aug 05
2025
|
Suzanne Louise Bruhn |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Aug 05
2025
|
Ivana Magovcevic Liebisch President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
222,687
-100.0%
|
-
|
|
Aug 05
2025
|
Cheryl R Blanchard |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Aug 05
2025
|
Gerhard Koenig |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
May 22
2025
|
Stefan Vitorovic |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
May 22
2025
|
Bruce Booth |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
May 22
2025
|
Mary Thistle |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
May 22
2025
|
Cheryl R Blanchard |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
May 22
2025
|
Haeberlein Samantha L. Budd |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+22.73%
|
-
|
|
May 22
2025
|
Gerhard Koenig |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
May 22
2025
|
Suzanne Louise Bruhn |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Dec 19
2024
|
Ivana Magovcevic Liebisch President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+2.2%
|
$5,000
$1.68 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 35K shares |
|---|---|
| Open market or private purchase | 27K shares |
| Sale (or disposition) back to the issuer | 11.9M shares |
|---|